Captrust Financial Advisors Aldeyra Therapeutics, Inc. Transaction History
Captrust Financial Advisors
- $30.9 Billion
- Q2 2024
A detailed history of Captrust Financial Advisors transactions in Aldeyra Therapeutics, Inc. stock. As of the latest transaction made, Captrust Financial Advisors holds 10,174 shares of ALDX stock, worth $61,450. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10,174
Previous 10,039
1.34%
Holding current value
$61,450
Previous $32,000
3.13%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding ALDX
# of Institutions
106Shares Held
35.1MCall Options Held
153KPut Options Held
83.9K-
Perceptive Advisors LLC New York, NY9.28MShares$56 Million0.89% of portfolio
-
Knoll Capital Management, LLC Miami, FL5.48MShares$33.1 Million12.24% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.74MShares$22.6 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.62MShares$21.9 Million0.0% of portfolio
-
Kennedy Capital Management, Inc. St Louis, MO1.6MShares$9.66 Million0.12% of portfolio
About Aldeyra Therapeutics, Inc.
- Ticker ALDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,323,100
- Market Cap $352M
- Description
- Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...